Fewer than one in 10 people eligible to benefit from obesity jabs like Wegovy are able to get them, states the WHO as it issues its first recommendations on the therapies.
Given in excess of 1,000,000,000 people worldwide now classified as obese, it is advocating for more widespread and fairer access to this class of drugs.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidelines recognises that excess weight is a lifelong illness that can be treated with thorough and lifelong support," stated the agency's head Tedros Adhanom Ghebreyesus.
High costs, constrained manufacturing, and supply-chain constraints are significant obstacles to broad access to the injections that can aid individuals in losing substantial body mass, notes the agency.
Skinny Jab Shortage
Despite the present most favorable outlook, the production of these medications might only reach around 100 million people – under 10% of the global need, according to the health organization.
The recommendation calls on nations and manufacturers to expand access, through measures such as licensing agreements.
A patent on the active ingredient – the main ingredient of the drug Wegovy – is set to lapse in a number of nations in 2026.
The Way Obesity Drugs Work
The injections replicate a biological compound to slow digestion, suppress the appetite and boost the sense of being full so individuals reduce food intake.
People typically see weight reduction in the initial weeks of commencing the once-weekly jabs.
Studies points to people may see weight return within a year of halting the medication, when their normal food cravings come back.
Being overweight or obese elevates your risk for experiencing health problems, such as diabetes, cardiovascular issues, brain attack, and some cancers.
Excess weight affects individuals in countries worldwide and was associated with millions of fatalities worldwide in 2024, as per the WHO.
